[Clinical experience with S-6436 in urinary tract infections (author's transl)]. 1977

H Yamamoto, and S Oida, and A Ohtsuki, and T Hosomi, and Y Kubo

S-6436 is a new preparation of sustained release cephalexin. Twenty-eight patients with urinary tract infections were orally given 500mg of S-6436 twice a day for about 7 days, and the following results were obtained: 1) Excellent clinical responses were observed in 8 cases, good in 18 cases and failure in 2 cases. Effectiveness was 93%. 2) As for the side effect, gastrointestinal symptoms were observed in one case out of 28 cases, but they disappeared after the completion of the treatment. No other side effects due to S-6436 were observed. S-6436 has as much effectiveness and safety as compared with usual cephalexin preparations. The frequency of the administration of S-6436 is twice a day, which means that S-6436 is more convenient in giving it to patients than usual cephalexin preparations.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002506 Cephalexin A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,Cefalexin,Cephalexin Dihydride,Cephalexin Hemihydrate,Cephalexin Hydrochloride,Cephalexin Monohydrate,Cephalexin Monohydrochloride,Cephalexin Monohydrochloride, Monohydrate,Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer,Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer,Cephalexin, (6R-(6alpha,7beta))-Isomer,Cephalexin, Monosodium Salt,Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer,Ceporexine,Palitrex
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H Yamamoto, and S Oida, and A Ohtsuki, and T Hosomi, and Y Kubo
October 1977, The Japanese journal of antibiotics,
H Yamamoto, and S Oida, and A Ohtsuki, and T Hosomi, and Y Kubo
June 1977, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
H Yamamoto, and S Oida, and A Ohtsuki, and T Hosomi, and Y Kubo
June 1977, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
H Yamamoto, and S Oida, and A Ohtsuki, and T Hosomi, and Y Kubo
October 1977, The Japanese journal of antibiotics,
H Yamamoto, and S Oida, and A Ohtsuki, and T Hosomi, and Y Kubo
October 1977, The Japanese journal of antibiotics,
H Yamamoto, and S Oida, and A Ohtsuki, and T Hosomi, and Y Kubo
June 1977, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
H Yamamoto, and S Oida, and A Ohtsuki, and T Hosomi, and Y Kubo
January 1978, The Japanese journal of antibiotics,
H Yamamoto, and S Oida, and A Ohtsuki, and T Hosomi, and Y Kubo
November 1977, The Japanese journal of antibiotics,
H Yamamoto, and S Oida, and A Ohtsuki, and T Hosomi, and Y Kubo
November 1977, The Japanese journal of antibiotics,
H Yamamoto, and S Oida, and A Ohtsuki, and T Hosomi, and Y Kubo
May 1981, MMW, Munchener medizinische Wochenschrift,
Copied contents to your clipboard!